Einzeltreffer — DigiBib

Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-γ-glutamic acid (such as γDLPGA) polypeptides of S. epidermidis, or related staphylococci that express a γPGA polypeptide. The γPGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses γPGA from the cap genes. Further, the expression of a γPGA polypeptide by the organism can then be altered.

Titel:	TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS
Autor/in / Beteiligte Person:	Otto, Michael ; Kocianova, Stanislava ; Vuong, Cuong ; Voyich, Jovanka ; Yao, Yufeng ; Fischer, Elizabeth ; De Leo, Frank
Link:	Zum Volltext
Veröffentlichung:	2012
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20120301481 Publication Date: November 29, 2012 Appl. No: 13/554245 Application Filed: July 20, 2012 Claim: 1. A method of treating an infection caused by a Staphylococcus organism that secretes poly-γ-glutamic acid (γPGA), comprising: selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses poly-γ-glutamic acid (γPGA); and interfering with secretion of a γPGA polypeptide by the organism, thereby treating the infection caused by the Staphylococcus organism. Claim: 2. The method of claim 1, wherein interfering with the secretion of the γPGA comprises promoting an immune response against the γPGA of the Staphylococcus organism, thereby promoting an effective immune response against the Staphylococcus organism. Claim: 3. The method of claim 2, wherein promoting the immune response against the γPGA comprises administering an effective amount of an immunogenic conjugate comprising a Staphylococcus capsular poly-γ-DL-glutamic acid (γDLPGA) polypeptide and an adjuvant. Claim: 4. The method of claim 2, wherein promoting the immune response against the γPGA comprises interfering with expression of the γPGA to increase immunodetection of the Staphylococcus organism. Claim: 5. The method of claim 4, wherein interfering with expression of the γPGA comprises inhibiting expression of the γPGA by cap genes. Claim: 6. The method of claim 2, wherein promoting the immune response against the γPGA comprises administering an effective amount of anti-γPGA antibodies sufficient to enhance an immune response against the Staphylococcus organism. Claim: 7. The method of claim 2, wherein interfering with the secretion of the γPGA comprises promoting an immune response against poly-γ-D-L-glutamic acid (γDLPGA). Claim: 8. The method of claim 7, wherein the γDLPGA includes γDPGA and γLPGA in substantially equivalent amounts. Claim: 9. The method of claim 1, wherein interfering with the secretion of the γPGA avoids formation of a biofilm associated with the organism. Claim: 10. The method of claim 1, wherein the Staphylococcus organism is S. capitis or S. warneri or S. saccharolyticus or S. caprae or S. hominis or S. haemolyticus or S. lugdunensis or S. simulans or S. epidermidis. Claim: 11. The method of claim 10, wherein the Staphylococcus organism is S. epidermidis. Claim: 12. The method of claim 1, wherein selecting the subject who is at risk comprises selecting a subject who has an in-dwelling medical device. Claim: 13. The method of claim 1, wherein the S. epidermidis infection is on an in-dwelling medical device. Claim: 14. A method of treating an S. epidermidis infection in a subject, comprising: enhancing an immune response against poly-γ-D-L-glutamic acid (γDLPGA) by administrating to the subject an antiserum against poly-γ-D-L-glutamic acid, thereby treating or preventing an S. epidermidis infection in a subject. Claim: 15. The method of claim 14, wherein the antiserum is administered to treat or inhibit a S. epidermidis infection on an in-dwelling medical device. Current U.S. Class: 4241/651 Current International Class: 61; 61; 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS